---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-093948"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T21:16:07.443721+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lineage Q4 net income $0.9M, full-year loss $63.5M; cash runway into Q2 2028

## Summary
- Q4 2025 revenue $6.6M (up from $2.9M YoY); net income $0.9M ($0.004 EPS) vs net loss $3.3M ($0.02 loss) in Q4 2024.
- Full-year 2025 net loss $63.5M ($0.28/share) vs $18.6M ($0.09/share) in 2024; driven by non-cash warrant remeasurement ($37.9M) and VAC impairment ($14.8M).
- Cash $55.8M at Dec 31, 2025; plus $5.4M from warrant exercises in March 2026; expected to support operations into Q2 2028.
- Achieved first milestone under Roche/Genentech collaboration for OpRegen; 36-month Phase 1/2a data shows sustained visual acuity gains.
- Launched Type 1 diabetes research initiative; treated first chronic SCI patient in OPC1 DOSED study with no safety events at 180 days.

## SEC filing metadata
- accession: 0001193125-26-093948
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000119312526093948/0001193125-26-093948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000119312526093948/lctx-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-093948
- JSON: https://secwatch.observer/filing/0001193125-26-093948.json
- Plain text: https://secwatch.observer/filing/0001193125-26-093948.txt

## Key facts
- Earnings Releases
  Lineage Cell Therapeutics, Inc. reported financial results for quarter and year ended December 31, 2025.
  - Period: quarter and year ended December 31, 2025
  - Result: reported results
  source text: On March 5, 2026, Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter and year ended December 31, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/876343/000119312526093948/0001193125-26-093948-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.